- Raised $30M funding round, Jan 2018
About
Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules.
This level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas.
Anima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators).
In addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.
Funding history · 1 round · $30.0M total
Q&A
- What is Anima Biotech's primary focus?
- Anima Biotech specializes in small-molecule mRNA drug discovery, utilizing its mRNA Lightning platform to identify selective small-molecule mRNA drugs and their mechanisms of action.
- When was Anima Biotech founded?
- Anima Biotech was founded in June 2014.
- How many employees does Anima Biotech have?
- Anima Biotech has 51-200 employees.
- What is the total amount of funding Anima Biotech has raised?
- Anima Biotech has raised a total of $30,000,000 USD.
- When was Anima Biotech's last funding round and who participated?
- Anima Biotech's last funding round was in January 2018, with participation from the National Institute of Health (NIH).
- Which pharmaceutical companies has Anima Biotech established strategic collaborations with?
- Anima Biotech has established strategic collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
- What therapeutic areas are Anima Biotech's wholly-owned pipeline programs focused on?
- Anima Biotech's wholly-owned pipeline programs are in fibrosis (collagen I mRNA biology modulators), oncology (c-Myc and mKras mRNA biology modulators), and neuroscience (Tau for Alzheimer's disease and Nav1.7 mRNA biology modulators for pain).
- Where is Anima Biotech's headquarters located?
- Anima Biotech's headquarters is located in Ramat Gan, Israel.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | animabiotech.com |
|---|---|
| linkedin.com/company/5385114 | |
| facebook.com/profile.php?id=100062978003577 |
Identifiers & details
| Former names | Anima Cell Metrology |
|---|---|
| Founded | 2014-6 |
| Employees (exact) | 62 |
| Offices | Bernardsville |
Radar intelligence
Patents
| EPO | 14 |
|---|
Web history (Wayback)
| Domain | animabiotech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 44 |
|---|